Therapy Trends: Multiple Sclerosis
An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.
Multiple Sclerosis: On the cusp of a treatment revolution
The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi’s Aubagio and Genzyme’s Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.
Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.
Drive your strategic decision-making with inside intelligence
Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.
Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.
Therapy Trends: Multiple Sclerosis is delivered in two complimentary formats:
Therapy Trends Intelligence Report: a concise, focused, in-depth market intelligence research report that examines the range of current and late-stage pipeline drugs to determine future trends in the treatment and diagnosis of MS, and assess the commercial impact on the MS market landscape.
Therapy Trends Impact Assessments: dynamic analyst briefings evaluating the impact of events in the MS market over the next 12 months, delivered to you within days of a significant event happening
Who should buy this report?
This report will be of value to senior pharma directors and managers with responsibilities in the following areas:
Multiple Sclerosis: On the cusp of a treatment revolution
The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi’s Aubagio and Genzyme’s Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.
Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.
Drive your strategic decision-making with inside intelligence
Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.
- We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time
- Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning
- Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market
- KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice
- Uncovering KOLs’ opinions on unmet needs enables you to identify potential commercial opportunities
- Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring
Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.
- What are the key unmet needs? There is a high risk, high reward opportunity in the development of a therapy with efficacy for progressive subtypes.
- How will therapies will be positioned against each other in the future of MS treatment? Biogen’s new oral therapy BG-12 is expected to usurp the current market leaders and become the first-line therapy of choice.
- How will treatment developments play out in the near future? Biogen's activity in broadening its robust pipeline shows its resolve in maintaining its leading position in MS.
- Is there potential for new players in the lucrative MS market? New entrants are set to capture significant share and cannibalise sales of the leading drugs.
- Where will Sanofi’s Lemtrada and Aubagio be positioned in treatment? Pricing and safety will play a large part in determining uptake of this highly effective drug
- How will the launch of biosimilars affect prescribing behavior? Pricing will be a key determinant in positioning and uptake
- How will Novartis’s Gilenya be affected by recent safety concerns? Long-term concerns have kept it from being the first line therapy.
- Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? This offers the first example of personalised medicine; a trend that will aid uptake in future.
Therapy Trends: Multiple Sclerosis is delivered in two complimentary formats:
Therapy Trends Intelligence Report: a concise, focused, in-depth market intelligence research report that examines the range of current and late-stage pipeline drugs to determine future trends in the treatment and diagnosis of MS, and assess the commercial impact on the MS market landscape.
Therapy Trends Impact Assessments: dynamic analyst briefings evaluating the impact of events in the MS market over the next 12 months, delivered to you within days of a significant event happening
Who should buy this report?
This report will be of value to senior pharma directors and managers with responsibilities in the following areas:
- Business Development
- New Product Planning
- Market Research
- Strategic brand planning
- Forecasting and marketing professionals
- Medical Affairs
- Clinical Trials
- Relationship Management
EXECUTIVE SUMMARY
INTRODUCTION
METHODOLOGY
CURRENT MULTIPLE SCLEROSIS MARKETPLACE
Current treatment landscape
Multiple sclerosis market definition
Current market overview
Current therapies
Cross trial comparisons is not an ideal assessment
Gilenya (fingolimod; Novartis) trends
Gilenya has first oral to market advantage
Gilenya raises bar for pipeline therapies entering the market
Deaths mar Gilenya's side effect profile and positions drug as a second line
Vigilance program is cumbersome and likely to restrict access
Gilenya's high price will restrict use
Clinical trials in progressive multiple sclerosis ongoing
Tysabri (natalizumab; Biogen/Elan) trends
Tysabri is the most effective approved multiple sclerosis therapy
PML fears positions drug as second or later line
JCV test will promote use and allay fears
Progressive multiple sclerosis trials ongoing for Tysabri
Copaxone (glatiramer acetate; Teva) trends
Copaxone is the leading selling multiple sclerosis therapy
Teva fights generic Copaxone applications
Interferon betas (Avonex, Betaseron, Rebif, Extavia) trends
Interferons are the mainstay of multiple sclerosis treatment
Needles have evolved to avoid injection site reactions
Biosimilar guidelines in place for interferons
Current treatment algorithm
Multiple sclerosis unmet needs
Unmet need 1: Efficacy for progressive subtypes
Unmet need 2: Therapies offering better clinical profiles
Unmet need 3: Drugs to halt or repair neuronal damage
Unmet need 4: Improving multiple sclerosis induced cognition dysfunction
Unmet need 5: Need for improved adherence
FUTURE THERAPY TRENDS
BG-12 (dimethyl fumarate; Biogen) trends
Impressive efficacy and safety means BG-12 will become the leading multiple sclerosis pill
BG-12 will become a first-line therapy and a major threat to Gilenya
Unknown tolerability profile could prevent uptake
Delay in efficacy and compliance are other barriers for uptake
Aubagio (teriflunomide; Sanofi/Genzyme) trends
Aubagio exhibits strong safety profile but has moderate efficacy
Aubagio has potential positioning as a combination therapy
Pricing will determine Aubagio's success
Laquinimod (Teva) trends
Phase III efficacy data is disappointing and less than current therapies
Compelling disability data suggests role in neuroprotection
Safety data and mechanism suits role as an add-on therapy
Lemtrada (alemtuzumab; Genzyme/Sanofi) trends
Lemtrada is one of the most effective pipeline therapies
Safety concerns may hamper uptake and reserve Lemtrada as a last-line or induction therapy
Sanofi will price Lemtrada in line with current treatments
Daclizumab HYP (Biogen/Abbott) trends
Daclizumab complements Biogen's portfolio with good safety and efficacy
Daclizumab positioning will be important for Biogen franchise
Ocrelizumab (Biogen/Roche) trends
Ocrelizumab represents the most advanced B-cell therapy
Ocrelizumab is highly effective in reducing relapses
Questionable long-term safety overshadows potential uptake
Future prescribing trends
More use of induction therapy in highly relapsing patients
Current first-line therapies will have a less prominent role in future treatment
Interferons and Copaxone can find a niche as combination therapies
Oral therapies will become the leading first- and second-line therapies
JCV test will drive earlier use of Tysabri
Potent but less safe therapies will remain last line
FUTURE DEVELOPMENTS IN MULTIPLE SCLEROSIS
Constrained pricing environments will reduce market access
Clinically isolated syndrome will be considered early stage multiple sclerosis in the future
Trend for earlier diagnosis and treatment will produce better outcomes
Trend to more symptomatic therapies being developed
Eventual development of biomarkers will aid treatment
Better understanding of underlying multiple sclerosis etiology
Methods to assess treatment failure could be implemented in the future
More emphasis should be placed on long-term outcome measures
FIRSTWORD MULTIPLE SCLEROSIS NEWS ANALYSIS
Positive multiple sclerosis key news events
Current therapies
Pipeline therapies
Company therapies
Negative multiple sclerosis news
Current therapies
Pipeline therapies
Company therapies
FUTURE OF MULTIPLE SCLEROSIS DIAGNOSIS AND TREATMENT
APPENDIX
KOL biographies
KOLs from North America
KOLs from Europe
APPENDIX
INTRODUCTION
METHODOLOGY
CURRENT MULTIPLE SCLEROSIS MARKETPLACE
Current treatment landscape
Multiple sclerosis market definition
Current market overview
Current therapies
Cross trial comparisons is not an ideal assessment
Gilenya (fingolimod; Novartis) trends
Gilenya has first oral to market advantage
Gilenya raises bar for pipeline therapies entering the market
Deaths mar Gilenya's side effect profile and positions drug as a second line
Vigilance program is cumbersome and likely to restrict access
Gilenya's high price will restrict use
Clinical trials in progressive multiple sclerosis ongoing
Tysabri (natalizumab; Biogen/Elan) trends
Tysabri is the most effective approved multiple sclerosis therapy
PML fears positions drug as second or later line
JCV test will promote use and allay fears
Progressive multiple sclerosis trials ongoing for Tysabri
Copaxone (glatiramer acetate; Teva) trends
Copaxone is the leading selling multiple sclerosis therapy
Teva fights generic Copaxone applications
Interferon betas (Avonex, Betaseron, Rebif, Extavia) trends
Interferons are the mainstay of multiple sclerosis treatment
Needles have evolved to avoid injection site reactions
Biosimilar guidelines in place for interferons
Current treatment algorithm
Multiple sclerosis unmet needs
Unmet need 1: Efficacy for progressive subtypes
Unmet need 2: Therapies offering better clinical profiles
Unmet need 3: Drugs to halt or repair neuronal damage
Unmet need 4: Improving multiple sclerosis induced cognition dysfunction
Unmet need 5: Need for improved adherence
FUTURE THERAPY TRENDS
BG-12 (dimethyl fumarate; Biogen) trends
Impressive efficacy and safety means BG-12 will become the leading multiple sclerosis pill
BG-12 will become a first-line therapy and a major threat to Gilenya
Unknown tolerability profile could prevent uptake
Delay in efficacy and compliance are other barriers for uptake
Aubagio (teriflunomide; Sanofi/Genzyme) trends
Aubagio exhibits strong safety profile but has moderate efficacy
Aubagio has potential positioning as a combination therapy
Pricing will determine Aubagio's success
Laquinimod (Teva) trends
Phase III efficacy data is disappointing and less than current therapies
Compelling disability data suggests role in neuroprotection
Safety data and mechanism suits role as an add-on therapy
Lemtrada (alemtuzumab; Genzyme/Sanofi) trends
Lemtrada is one of the most effective pipeline therapies
Safety concerns may hamper uptake and reserve Lemtrada as a last-line or induction therapy
Sanofi will price Lemtrada in line with current treatments
Daclizumab HYP (Biogen/Abbott) trends
Daclizumab complements Biogen's portfolio with good safety and efficacy
Daclizumab positioning will be important for Biogen franchise
Ocrelizumab (Biogen/Roche) trends
Ocrelizumab represents the most advanced B-cell therapy
Ocrelizumab is highly effective in reducing relapses
Questionable long-term safety overshadows potential uptake
Future prescribing trends
More use of induction therapy in highly relapsing patients
Current first-line therapies will have a less prominent role in future treatment
Interferons and Copaxone can find a niche as combination therapies
Oral therapies will become the leading first- and second-line therapies
JCV test will drive earlier use of Tysabri
Potent but less safe therapies will remain last line
FUTURE DEVELOPMENTS IN MULTIPLE SCLEROSIS
Constrained pricing environments will reduce market access
Clinically isolated syndrome will be considered early stage multiple sclerosis in the future
Trend for earlier diagnosis and treatment will produce better outcomes
Trend to more symptomatic therapies being developed
Eventual development of biomarkers will aid treatment
Better understanding of underlying multiple sclerosis etiology
Methods to assess treatment failure could be implemented in the future
More emphasis should be placed on long-term outcome measures
FIRSTWORD MULTIPLE SCLEROSIS NEWS ANALYSIS
Positive multiple sclerosis key news events
Current therapies
Pipeline therapies
Company therapies
Negative multiple sclerosis news
Current therapies
Pipeline therapies
Company therapies
FUTURE OF MULTIPLE SCLEROSIS DIAGNOSIS AND TREATMENT
APPENDIX
KOL biographies
KOLs from North America
KOLs from Europe
APPENDIX
